Vumerity, also known as diroximel fumarate, is a medication developed by Biogen for the treatment of relapsing forms of multiple sclerosis (MS) [1]. It is an oral therapy [1].
What is Vumerity used for?
Vumerity is indicated for the treatment of patients with relapsing forms of multiple sclerosis [1]. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1].
How does Vumerity work?
Vumerity is a fumaric acid ester that is converted to monomethyl fumarate (MMF) in the body [1]. MMF is thought to exert its therapeutic effects through the activation of the nuclear factor (erythroid-2-related factor 2) antioxidant response element (ARE) pathway [1]. This pathway is believed to play a role in protecting against oxidative stress, a mechanism implicated in the pathogenesis of MS [1].
What are the benefits of Vumerity compared to other MS treatments?
Vumerity offers a favorable gastrointestinal (GI) tolerability profile compared to other fumarate-based therapies, such as Tecfidera (dimethyl fumarate) [2]. This is attributed to its distinct chemical structure, which leads to less systemic exposure to a reactive intermediate responsible for GI side effects [2]. Clinical trials have shown that patients treated with Vumerity experienced significantly fewer GI-related adverse events like diarrhea, nausea, and abdominal pain [2].
When does Vumerity's patent expire?
Information regarding specific patent expiry dates for Vumerity may vary and is best accessed through specialized patent databases. Resources like DrugPatentWatch.com provide detailed patent landscapes for pharmaceutical products, including Vumerity [3].
Who manufactures Vumerity?
Biogen is the pharmaceutical company that developed and manufactures Vumerity [1].
What are the potential side effects of Vumerity?
Common side effects of Vumerity include flushing, diarrhea, nausea, and abdominal pain [1]. More serious but less common side effects can include liver enzyme elevations, a decrease in lymphocyte count (lymphopenia), and progressive multifocal leukoencephalopathy (PML) [1].
Can biosimilars be developed for Vumerity?
The development of biosimilars for Vumerity would be contingent on the expiry of its relevant patents and regulatory pathways for biosimilar approval. The complexity of oral small molecules can present different challenges for biosimilar development compared to biologics.
What is the clinical data supporting Vumerity's efficacy?
Clinical studies have demonstrated Vumerity's efficacy in reducing the annualized relapse rate and the accumulation of new T2 lesions on MRI in patients with relapsing forms of MS [1]. These findings were reported in pivotal trials such as the defining studies for its approval.
How does Vumerity fit into the MS treatment landscape?
Vumerity provides an oral treatment option for relapsing MS with a focus on improved GI tolerability. It offers an alternative for patients who may not tolerate other fumarate therapies or are seeking an oral disease-modifying treatment [2].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/